Department of Pharmaceutical Sciences, UConn, Storrs, CT 06269, United States.
Department of Pharmaceutical Sciences, UConn, Storrs, CT 06269, United States.
Int J Pharm. 2022 May 10;619:121700. doi: 10.1016/j.ijpharm.2022.121700. Epub 2022 Mar 28.
Liposomes were one of the earliest drug delivery vehicles used for anti-cancer therapeutics and similarly, lipid-based nanoparticles have been used for abundance of applications as gene therapies. The methods to produce these particles have remained relatively unchanged until the recent emergence of continuous manufacturing. Continuous processing enables accelerated development of nanoparticle formulations while providing a scalable manufacturing solution. For this work a continuous processing platform for the production of lipid and polymeric-based nanoparticle formulations has been developed at the University of Connecticut. This research focuses on the formation of liposomes encompassing multiple design of experiments (DoEs) to identify functional relationships between critical process parameters (CPPs), critical material attributes (CMAs), and critical quality attributes (CQAs) for liposomal formulations produced using this continuous processing platform. Liposomes of various sizes and of low polydispersity index (PDI) were produced with different material attributes under various processing conditions. In general, lower mole percentages of cholesterol produced larger particles whereas the mole percent of phosphatidylglycerol did not seem to have a s impact on the size of the liposomes that were produced. The results showed that similarly sized liposomes could be produced with different processing conditions allowing for the flexibility to operate in regions most suitable for formulation components that may be sensitive to certain processing conditions. For example, if the target size of a formulation is 100 nm but the active pharmaceutical ingredient is sensitive to temperature, then the formulation can be manufactured at high (55 °C) or low (30 °C) depending on its characteristics. Additionally, the relationships between CMAs and CPPs were different from conventional liposomal manufacturing methods, allowing for more flexibility when using a continuous processing system. Models that can effectively predict the hydrodynamic diameter of monodispersed liposomes produced using continuous processing were developed. The models developed from the DoEs in this study may be useful for accelerated development of new lipid formulations as well as facilitate the translation from traditional manufacturing methods to continuous manufacturing for products already on the market.
脂质体是最早用于抗癌治疗的药物输送载体之一,类似地,基于脂质的纳米粒子也被广泛应用于基因治疗等领域。直到最近连续制造技术的出现,这些粒子的生产方法才保持相对不变。连续处理能够加速纳米粒子配方的开发,同时提供可扩展的制造解决方案。为此,康涅狄格大学开发了一种用于生产脂质和聚合物纳米粒子配方的连续处理平台。本研究侧重于形成脂质体,涵盖了多项实验设计 (DoE),以确定使用这种连续处理平台生产的脂质体配方中关键工艺参数 (CPP)、关键材料属性 (CMA) 和关键质量属性 (CQA) 之间的功能关系。使用不同的材料属性在不同的处理条件下生产了各种大小和低多分散指数 (PDI) 的脂质体。一般来说,胆固醇的摩尔百分比越低,产生的颗粒越大,而磷脂酰甘油的摩尔百分比似乎对所产生的脂质体的大小没有影响。结果表明,在最适合可能对某些处理条件敏感的配方成分的区域中,可以使用不同的处理条件生产类似大小的脂质体,从而具有更大的灵活性。例如,如果配方的目标尺寸为 100nm,但活性药物成分对温度敏感,则可以根据其特性在高温(55°C)或低温(30°C)下制造配方。此外,CMA 和 CPP 之间的关系与传统的脂质体制造方法不同,这使得在使用连续处理系统时具有更大的灵活性。本研究中的 DoE 开发了能够有效预测使用连续处理生产的单分散脂质体水动力直径的模型。这些模型可能有助于加速新脂质配方的开发,并促进从传统制造方法向已上市产品的连续制造的转化。